Prostatic Arterial Embolization to Treat Benign Prostatic Hyperplasia

Bibliographic Details
Main Author: Pisco, JM
Publication Date: 2011
Other Authors: Pinheiro, LC, Bilhim, T, Duarte, M, Mendes, J, Oliveira, A
Format: Article
Language: eng
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: http://hdl.handle.net/10400.17/1193
Summary: PURPOSE: To evaluate whether prostatic arterial embolization (PAE) might be a feasible procedure to treat lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: Fifteen patients (age range, 62-82 years; mean age, 74.1 y) with symptomatic BPH after failure of medical treatment were selected for PAE with nonspherical 200-μm polyvinyl alcohol particles. The procedure was performed by a single femoral approach. Technical success was considered when selective prostatic arterial catheterization and embolization was achieved on at least one pelvic side. RESULTS: PAE was technically successful in 14 of the 15 patients (93.3%). There was a mean follow-up of 7.9 months (range, 3-12 months). International Prostate Symptom Score decreased a mean of 6.5 points (P = .005), quality of life improved 1.14 points (P = .065), International Index of Erectile Function increased 1.7 points (P = .063), and peak urinary flow increased 3.85 mL/sec (P = .015). There was a mean prostate-specific antigen reduction of 2.27 ng/mL (P = .072) and a mean prostate volume decrease of 26.5 mL (P = .0001) by ultrasound and 28.9 mL (P = .008) by magnetic resonance imaging. There was one major complication (a 1.5-cm(2) ischemic area of the bladder wall) and four clinical failures (28.6%). CONCLUSIONS: In this small group of patients, PAE was a feasible procedure, with preliminary results and short-term follow-up suggesting good symptom control without sexual dysfunction in suitable candidates, associated with a reduction in prostate volume.
id RCAP_8a2ca896069eaebbf71b1bf84956148b
oai_identifier_str oai:repositorio.chlc.pt:10400.17/1193
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Prostatic Arterial Embolization to Treat Benign Prostatic HyperplasiaArtériasBiópsiaEmbolização TerapêuticaEfeitos AdversosEstudos de ViabilidadeIsquemiaRessonância MagnéticaTamanho do ÓrgãoErecção do PénisProjectos PilotoÁlcool de PolivinilPortugalEstudos ProspectivosPróstataUltrassonografiaAntigénio Prostático EspecíficoHiperplasia ProstáticaQualidade de VidaRecuperação da Função FisiológicaFactores de TempoResultado de TratamentoBexigaUrodinâmicaPURPOSE: To evaluate whether prostatic arterial embolization (PAE) might be a feasible procedure to treat lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: Fifteen patients (age range, 62-82 years; mean age, 74.1 y) with symptomatic BPH after failure of medical treatment were selected for PAE with nonspherical 200-μm polyvinyl alcohol particles. The procedure was performed by a single femoral approach. Technical success was considered when selective prostatic arterial catheterization and embolization was achieved on at least one pelvic side. RESULTS: PAE was technically successful in 14 of the 15 patients (93.3%). There was a mean follow-up of 7.9 months (range, 3-12 months). International Prostate Symptom Score decreased a mean of 6.5 points (P = .005), quality of life improved 1.14 points (P = .065), International Index of Erectile Function increased 1.7 points (P = .063), and peak urinary flow increased 3.85 mL/sec (P = .015). There was a mean prostate-specific antigen reduction of 2.27 ng/mL (P = .072) and a mean prostate volume decrease of 26.5 mL (P = .0001) by ultrasound and 28.9 mL (P = .008) by magnetic resonance imaging. There was one major complication (a 1.5-cm(2) ischemic area of the bladder wall) and four clinical failures (28.6%). CONCLUSIONS: In this small group of patients, PAE was a feasible procedure, with preliminary results and short-term follow-up suggesting good symptom control without sexual dysfunction in suitable candidates, associated with a reduction in prostate volume.ElsevierRepositório da Unidade Local de Saúde São JoséPisco, JMPinheiro, LCBilhim, TDuarte, MMendes, JOliveira, A2013-03-27T17:21:26Z20112011-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.17/1193enginfo:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2025-03-06T16:46:14Zoai:repositorio.chlc.pt:10400.17/1193Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-29T00:17:15.949832Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Prostatic Arterial Embolization to Treat Benign Prostatic Hyperplasia
title Prostatic Arterial Embolization to Treat Benign Prostatic Hyperplasia
spellingShingle Prostatic Arterial Embolization to Treat Benign Prostatic Hyperplasia
Pisco, JM
Artérias
Biópsia
Embolização Terapêutica
Efeitos Adversos
Estudos de Viabilidade
Isquemia
Ressonância Magnética
Tamanho do Órgão
Erecção do Pénis
Projectos Piloto
Álcool de Polivinil
Portugal
Estudos Prospectivos
Próstata
Ultrassonografia
Antigénio Prostático Específico
Hiperplasia Prostática
Qualidade de Vida
Recuperação da Função Fisiológica
Factores de Tempo
Resultado de Tratamento
Bexiga
Urodinâmica
title_short Prostatic Arterial Embolization to Treat Benign Prostatic Hyperplasia
title_full Prostatic Arterial Embolization to Treat Benign Prostatic Hyperplasia
title_fullStr Prostatic Arterial Embolization to Treat Benign Prostatic Hyperplasia
title_full_unstemmed Prostatic Arterial Embolization to Treat Benign Prostatic Hyperplasia
title_sort Prostatic Arterial Embolization to Treat Benign Prostatic Hyperplasia
author Pisco, JM
author_facet Pisco, JM
Pinheiro, LC
Bilhim, T
Duarte, M
Mendes, J
Oliveira, A
author_role author
author2 Pinheiro, LC
Bilhim, T
Duarte, M
Mendes, J
Oliveira, A
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório da Unidade Local de Saúde São José
dc.contributor.author.fl_str_mv Pisco, JM
Pinheiro, LC
Bilhim, T
Duarte, M
Mendes, J
Oliveira, A
dc.subject.por.fl_str_mv Artérias
Biópsia
Embolização Terapêutica
Efeitos Adversos
Estudos de Viabilidade
Isquemia
Ressonância Magnética
Tamanho do Órgão
Erecção do Pénis
Projectos Piloto
Álcool de Polivinil
Portugal
Estudos Prospectivos
Próstata
Ultrassonografia
Antigénio Prostático Específico
Hiperplasia Prostática
Qualidade de Vida
Recuperação da Função Fisiológica
Factores de Tempo
Resultado de Tratamento
Bexiga
Urodinâmica
topic Artérias
Biópsia
Embolização Terapêutica
Efeitos Adversos
Estudos de Viabilidade
Isquemia
Ressonância Magnética
Tamanho do Órgão
Erecção do Pénis
Projectos Piloto
Álcool de Polivinil
Portugal
Estudos Prospectivos
Próstata
Ultrassonografia
Antigénio Prostático Específico
Hiperplasia Prostática
Qualidade de Vida
Recuperação da Função Fisiológica
Factores de Tempo
Resultado de Tratamento
Bexiga
Urodinâmica
description PURPOSE: To evaluate whether prostatic arterial embolization (PAE) might be a feasible procedure to treat lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: Fifteen patients (age range, 62-82 years; mean age, 74.1 y) with symptomatic BPH after failure of medical treatment were selected for PAE with nonspherical 200-μm polyvinyl alcohol particles. The procedure was performed by a single femoral approach. Technical success was considered when selective prostatic arterial catheterization and embolization was achieved on at least one pelvic side. RESULTS: PAE was technically successful in 14 of the 15 patients (93.3%). There was a mean follow-up of 7.9 months (range, 3-12 months). International Prostate Symptom Score decreased a mean of 6.5 points (P = .005), quality of life improved 1.14 points (P = .065), International Index of Erectile Function increased 1.7 points (P = .063), and peak urinary flow increased 3.85 mL/sec (P = .015). There was a mean prostate-specific antigen reduction of 2.27 ng/mL (P = .072) and a mean prostate volume decrease of 26.5 mL (P = .0001) by ultrasound and 28.9 mL (P = .008) by magnetic resonance imaging. There was one major complication (a 1.5-cm(2) ischemic area of the bladder wall) and four clinical failures (28.6%). CONCLUSIONS: In this small group of patients, PAE was a feasible procedure, with preliminary results and short-term follow-up suggesting good symptom control without sexual dysfunction in suitable candidates, associated with a reduction in prostate volume.
publishDate 2011
dc.date.none.fl_str_mv 2011
2011-01-01T00:00:00Z
2013-03-27T17:21:26Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.17/1193
url http://hdl.handle.net/10400.17/1193
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833600472137596928